<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01600274</url>
  </required_header>
  <id_info>
    <org_study_id>1229ed09ct</org_study_id>
    <nct_id>NCT01600274</nct_id>
  </id_info>
  <brief_title>Bioavailability Study With Oral Single Dose Administration of Ethinylestradiol and Dienogest</brief_title>
  <official_title>Characterisation of Relative Bioavailability and Assessment of Bioequivalence of a Newly Developed Ethinylestradiol/Dienogest IR Formulation in Comparison With a Marketed Reference Product (Valette®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharbil Waltrop GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharbil Waltrop GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Characterisation of relative bioavailability of Diena (Test) in comparison to Valette®
           (Reference) after single dose administration under fasting conditions

        -  Assessment of bioequivalence of Test vs. Reference after single dose administration
           under fasting conditions, determined by use of area under the concentration time curve
           AUC0-tlast and maximum concentration Cmax obtained for ethinylestradiol (EE) and
           dienogest (DNG)

        -  Descriptive characterisation of safety and tolerability of the investigational products
           in the study population
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax and AUC0-tlast of EE and DNG after each treatment</measure>
    <time_frame>K PK blood sampling will be performed pre-dose (within 1.5 h prior to administration) as well as 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18, 24, 36, 48 and 60 h p.a.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clast, AUCexpol%, AUC0-∞, tmax, t1/2, tlast, λ, MRT, tlag of EE and DNG after each treatment</measure>
    <time_frame>K PK blood sampling will be performed pre-dose (within 1.5 h prior to administration) as well as 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 18, 24, 36, 48 and 60 h p.a</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Female</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethyinylestradiol Dienogest combination</intervention_name>
    <description>A: One tablet of Test B: One tablet of Reference
2 x 0.03 mg EE = 0.06 mg EE 2 x 2 mg DNG = 4 mg DNG</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. sex: female

          2. ethnic origin: Caucasian

          3. age: 18 - 55 years, inclusive

          4. body-mass index (BMI): more than 19 kg/m² and less than 27 kg/m²

          5. good state of health

          6. non-smoker or an ex-smoker for a least 6 months

          7. written informed consent, after having been informed about benefits and potential
             risks of the trial, as well as details of the insurance taken out to cover the
             subject's participating in the study

        Exclusion Criteria:

        Subjects cannot be included if they match any of the following exclusion criteria:

        Safety concerns

          1. existing cardiac or haematological diseases and/or pathological findings, which might
             interfere with the safety, tolerability, absorption and/or pharmacokinetics of the
             active ingredient

          2. existing hepatic and/or renal diseases and/or pathological findings, which might
             interfere with the safety, tolerability, absorption and/or pharmacokinetics of the
             active ingredient

          3. existing gastrointestinal diseases and/or pathological findings, which might interfere
             with the safety, tolerability, absorption and/or pharmacokinetics of the active
             ingredient

          4. history of relevant CNS and/or psychiatric disorders and/or currently treated CNS
             and/or psychiatric disorders

          5. pathological ECG (12 standard leads) which might interfere with the safety of the
             active ingredient

          6. known allergic reactions to the active ingredients used or to constituents of the
             pharmaceutical preparations

          7. subjects with severe allergies or multiple drug allergies

          8. systolic blood pressure &gt; 160 mmHg

          9. diastolic blood pressure &gt; 90 mmHg

         10. heart rate &lt; 45 and &gt; 100 bpm

         11. laboratory values out of normal range unless the deviation from normal is judged as
             not relevant for the study by the investigator

         12. positive anti-HIV-test, HBs-AG-test or anti-HCV-test

         13. presence or history of venous or arterial thrombosis (e.g. deep venous thrombosis,
             pulmonary embolism, myocardial infarction and prodromal conditions (e.g. transient
             ischaemic attack, angina pectoris)), predisposition for venous or arterial thrombosis
             (e.g. APC-resistance, antithrombin-III-deficiency, protein C deficiency, protein S
             deficiency or other thrombogene coagulopathy, heart valve disorders or thrombogene
             cardiac dysrhythmias)

         14. presence or history of liver tumours or known or suspected sex-hormone influenced
             malignancies (e.g. of the breasts or endometrium)

         15. unclarified vaginal bleeding or amenorrhoe

         16. subjects with fructose or galactose intolerance, deficiency of lactase,
             saccharase-isomaltase or malabsortion of glucose/galactose Lack of suitability for the
             trial

         17. acute or chronic diseases which could affect absorption or metabolism

         18. history of or current drug or alcohol dependence

         19. regular intake of alcoholic food or beverages of ≥ 20 g per day

         20. subjects who are on a diet which could affect the pharmacokinetics of the active
             ingredient

         21. regular intake of caffeine containing food or beverages of ≥ 500 mg per day

         22. blood donation or other blood loss of more than 400 ml within the last two months
             prior to individual enrolment of the subject

         23. participation in a clinical trial during the last two months prior to individual
             enrolment of the subject

         24. regular treatment with any systemically available medication (except usual replacement
             therapy with L-thyroxine)

         25. subjects, who report a frequent occurrence of migraine attacks

         26. use of hormonal preparations within 6 weeks (oral, transdermal, vaginal), 2 months
             (intramuscularly administered depot preparations used once per month) or 6 months
             (intramuscularly administered depot preparations used once per 3 month) before
             pre-study examination

             For female subjects with childbearing potential only:

         27. positive pregnancy test at pre-study examination

         28. pregnant or lactating women

         29. female subjects who do not agree to apply adequate non-hormonal and highly effective
             contraceptive methods as defined in Note for Guidance on Non-Clinical Safety Studies
             for the Conduct of Human Clinical Trials for Pharmaceuticals (CPMP/ICH/286/95,
             modification), November 2000 Administrative reasons

         30. subjects suspected or known not to follow instructions

         31. subjects who are unable to understand the written and verbal instructions, in
             particular regarding the risks and inconveniences they will be exposed to during their
             participation in the study The exclusion criteria are chosen to assure that subjects
             with specific risks for administration of the investigated medicinal products and
             subjects with conditions, which may have an impact on pharmacokinetic parameters,
             cannot be included.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2012</study_first_submitted>
  <study_first_submitted_qc>May 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Nandrolone</mesh_term>
    <mesh_term>Dienogest</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 21, 2012</submitted>
    <returned>June 22, 2012</returned>
    <submitted>June 27, 2012</submitted>
    <returned>July 31, 2012</returned>
    <submitted>October 26, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

